Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical announced today that it received FDA approval for its Ponvory treatment.
Ponvory (ponesimod) is a once-daily, oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator for treating adults with relapsing forms of multiple sclerosis (MS). It’s areas of treatment include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.
Filed Under: clinical trials, Drug Delivery, Drug Discovery, Drug Discovery and Development, Neurological Disease
Tell Us What You Think!
You must be logged in to post a comment.